Chemotherapy for advanced colorectal cancer: It can improve quality of care and offer modest increases in survival

BMJ

Volumn 321, Issue 7260, 2000, Pages 521-522

  Michael, M ^a   Zalcberg, J R ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FLOXURIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; METHOTREXATE;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; COLORECTAL CANCER; COST EFFECTIVENESS ANALYSIS; EDITORIAL; META ANALYSIS; PRIORITY JOURNAL; QUALITY OF LIFE; SURVIVAL RATE;

ANTIMETABOLITES, ANTINEOPLASTIC; COLORECTAL NEOPLASMS; COST-BENEFIT ANALYSIS; DRUG COSTS; FLUOROURACIL; HUMANS; META-ANALYSIS; PALLIATIVE CARE; RANDOMIZED CONTROLLED TRIALS; SURVIVAL ANALYSIS;

EID: 0034596519     PISSN: 09598138     EISSN: 14685833     Source Type: Journal    
DOI: 10.1136/bmj.321.7260.521     Document Type: Editorial

References (12)

1. Parkin DM, Pisani P, Ferlay J. Cancer statistics. CA Cancer J Clin 1999; 49: 33-64.
2. Colorectal Cancer Collaborative Group. Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. BMJ 2000; 321: 531-535.
3. Guyatt GH, Feeney DH, Patrick DL. Measuring health-related quality of life. Ann Intern Med 1993; 118: 622-629.
4. Nordic Gastrointestinal Tumour Adjuvant Therapy Group. Expectant or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial. J Clin Oncol 1992; 10: 904-911.
5. Glimelius B, Graf W, Hoffman K, Pahlman L, Sjoden PO, Wenberg A. General condition of asymptomatic patients with advanced colorectal cancer receiving palliative chemotherapy. A longitudinal study. Acta Oncol 1992; 31: 645-651.
6. Cunningham D, Pryhonen S, James RD, Punt CJA, Hickish TF, Heikkila R, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1999; 352: 1413-1418.
7. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treament of Cancer QLQ-C30: a quality-of-life instrument for use in international trials in oncology. J Natl Cancer Inst 1993; 85: 365-376.
8. Bloomfield DJ, Krahn MD, Neogi T, Panzarella T, Smith TJ, Warde P, et al. Economic evaluation of chemotherapy with mitoxantrone plus prednisone for symptomatic hormone-resistant prostate cancer: based on a Canadian randomized trial with palliative end points. J Clin Oncol 1998; 16: 2272-2279.
9. Coukell AJ, Noble S, Faulds D. Vinorelbine in advanced non-small cell cancer. A pharmacoeconomic review. Pharmacoeconomics 1999; 15: 405-417.
10. Cunningham D, Falk S, Jackson D. Irinotecan and infusional 5-fluorouracil as first line treatment of metastatic colorectal cancer: improved survival and cost-effective compared with infusional 5-FU [abstract]. Proc Am Soc Clin Oncol 2000; 19: 981A.
11. Meta-analysis Group in Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 1998; 16: 301-308.
12. Buyse M, Thirion P, Carlson RW, Burzykowski T, Molenberghs G, Piedbois P, et al. Relation between tumour reponse to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis. Lancet 2000; 356: 373-378.